Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P David Rogers

Showing results (21-30 of 104) with videos related to

Pageof 11
Sort By:
Antimicrobial Agents and Chemotherapy|February 24, 2011
Differential requirement of the transcription factor Mcm1 for activation of the Candida albicans multidrug efflux pump MDR1 by its regulators Mrr1 and Cap1Selene Mogavero, Arianna Tavanti, Sonia Senesi, et al.
Antimicrobial Agents and Chemotherapy|July 25, 2018
Relative Contribution of the ABC Transporters Cdr1, Pdh1, and Snq2 to Azole Resistance in Candida glabrataSarah G Whaley, Qing Zhang, Kelly E Caudle, et al.
Antimicrobial Agents and Chemotherapy|February 11, 2010
Changes in the proteome of Candida albicans in response to azole, polyene, and echinocandin antifungal agentsChristopher F Hoehamer, Edwin D Cummings, George M Hilliard, et al.
Antimicrobial Agents and Chemotherapy|September 26, 2018
A Hyperactive Form of the Zinc Cluster Transcription Factor Stb5 Causes <i>YOR1</i> Overexpression and Beauvericin Resistance in Candida albicansBernardo Ramírez-Zavala, Hannah Manz, Frank Englert, et al.
Antimicrobial Agents and Chemotherapy|March 16, 2026
Deciphering the multidrug resistance paradigm in <i>Candida auris</i>Darian J Santana, Nicholas C Cauldron, P David Rogers, et al.
Pharmacotherapy|November 25, 2015
Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal AgentJeffrey M Rybak, Kayleigh R Marx, Andrew T Nishimoto, et al.
The Journal of Antimicrobial Chemotherapy|February 4, 2003
The activity of amphotericin B against Candida albicans is not directly associated with extracellular calcium concentrationP David Rogers, Robert E Kramer, Janice K Crews, et al.
The Annals of Pharmacotherapy|March 18, 2003
Voriconazole: a new triazole antifungal agentMargaret M Pearson, P David Rogers, John D Cleary, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2019
Contribution of Clinically Derived Mutations in the Gene Encoding the Zinc Cluster Transcription Factor Mrr2 to Fluconazole Antifungal Resistance and <i>CDR1</i> Expression in <i>Candida albicans</i>Andrew T Nishimoto, Qing Zhang, Brandon Hazlett, et al.
The Journal of Antimicrobial Chemotherapy|June 1, 2006
Proteomic analysis of experimentally induced azole resistance in Candida glabrataP David Rogers, John-Paul Vermitsky, Thomas D Edlind, et al.
Pageof 11

Showing results (21-30 of 104) with videos related to

Sort By:
Pageof 11
Antimicrobial Agents and Chemotherapy|February 24, 2011
Differential requirement of the transcription factor Mcm1 for activation of the Candida albicans multidrug efflux pump MDR1 by its regulators Mrr1 and Cap1Selene Mogavero, Arianna Tavanti, Sonia Senesi, et al.
Antimicrobial Agents and Chemotherapy|July 25, 2018
Relative Contribution of the ABC Transporters Cdr1, Pdh1, and Snq2 to Azole Resistance in Candida glabrataSarah G Whaley, Qing Zhang, Kelly E Caudle, et al.
Antimicrobial Agents and Chemotherapy|February 11, 2010
Changes in the proteome of Candida albicans in response to azole, polyene, and echinocandin antifungal agentsChristopher F Hoehamer, Edwin D Cummings, George M Hilliard, et al.
Antimicrobial Agents and Chemotherapy|September 26, 2018
A Hyperactive Form of the Zinc Cluster Transcription Factor Stb5 Causes <i>YOR1</i> Overexpression and Beauvericin Resistance in Candida albicansBernardo Ramírez-Zavala, Hannah Manz, Frank Englert, et al.
Antimicrobial Agents and Chemotherapy|March 16, 2026
Deciphering the multidrug resistance paradigm in <i>Candida auris</i>Darian J Santana, Nicholas C Cauldron, P David Rogers, et al.
Pharmacotherapy|November 25, 2015
Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal AgentJeffrey M Rybak, Kayleigh R Marx, Andrew T Nishimoto, et al.
The Journal of Antimicrobial Chemotherapy|February 4, 2003
The activity of amphotericin B against Candida albicans is not directly associated with extracellular calcium concentrationP David Rogers, Robert E Kramer, Janice K Crews, et al.
The Annals of Pharmacotherapy|March 18, 2003
Voriconazole: a new triazole antifungal agentMargaret M Pearson, P David Rogers, John D Cleary, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2019
Contribution of Clinically Derived Mutations in the Gene Encoding the Zinc Cluster Transcription Factor Mrr2 to Fluconazole Antifungal Resistance and <i>CDR1</i> Expression in <i>Candida albicans</i>Andrew T Nishimoto, Qing Zhang, Brandon Hazlett, et al.
The Journal of Antimicrobial Chemotherapy|June 1, 2006
Proteomic analysis of experimentally induced azole resistance in Candida glabrataP David Rogers, John-Paul Vermitsky, Thomas D Edlind, et al.
Pageof 11